| 100 ng/kg/day TCDD | 30 ng/kg/day PCB126 | 300 ng/kg/day PCB126 | 1000 ng/kg/day PCB126 | 1000 μg/kg/day PCB153 |
---|---|---|---|---|---|
Number of Rats Examined | 53 | 55 | 53 | 53 | 53 |
Hepatocyte Hypertrophy | 52**a | 23** | 42**a | 49**a | 39**a |
Multinucleated Hepatocytes | 51**b | 2 | 19** | 49**b | NA |
Fatty Change, Diffuse | 48**b | 7 | 30** | 47**b | 21** |
Bile Duct Hyperplasia | 53**b | 7 | 14** | 45**b | 10 |
Bile Duct Cyst | 21** | 6 | 3 | 12* | NA |
Oval Cell, Hyperplasia | 53** | 1 | 10** | 40** | NA |
Necrosis | 17** | 2 | 11 | 17** | NA |
Pigmentation | 53**b | 11** | 48**b | 48**b | 5 |
Eosiniphilic Focus | 44** | 10 | 17 | 17 | NA |
Inflammation | 49** | 40 | 51** | 51** | NA |
Nodular Hyperplasia | 36** | NA | 3 | 39** | 1 |
Portal Fibrosis | 27** | NA | 2 | 10** | NA |
Cholangiofibrosis | 31** | 1 | 3 | 22** | 1 |
Toxic Hepatopathy | 53**b | 6* | 39** | 49**b | NA |
Hepatocholangioma | 17** | NA | NA | 3 | 2 |
Hepatocellular Adenoma | 13** | 2 | 2 | 7* | NA |
Cholangiocarcinoma | 25** | NA | 5* | 22** | NA |